## Tadliq (tadalafil susp) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

| MEMBER'S LAST NAME:  | MEMBER'S FIRST NAME:   |  |
|--|--|--|
| · · · · · · · · · · · · · · · · · · ·  | tely and legibly. Attach any additional documentation that is support the authorization request). Information contained in |  |
| MEMBER INFORMATION   | URGENT   |  |
| LAST NAME:   | FIRST NAME:  |  |
|  |  |  |
| PHONE NUMBER:  | DATE OF BIRTH:   |  |
| STREET ADDRESS:  |  |  |
| CITY:  | STATE: ZIP CODE:   |  |
| PATIENT INSURANCE ID NUMBER:   |  |  |
| IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DIS FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP  PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABL AUTHORIZED REPRESENTATIVE) | E):  |  |
| PRESCRIBER INFORMATION   |  |  |
| LAST NAME:   | FIRST NAME:  |  |
| PRESCRIBER SPECIALTY:  | EMAIL ADDRESS:   |  |
| NPI NUMBER:  | DEA NUMBER:  |  |
| PHONE NUMBER:  | FAX NUMBER:  |  |
| STREET ADDRESS:  |  |  |
| CITY:  | STATE: ZIP CODE:   |  |
| REQUESTOR (if different than prescriber):  | OFFICE CONTACT PERSON:   |  |
|  |  |  |
| MEDICATION OR MEDICAL DISPENSING INFORMATION   |  |  |
| MEDICATION NAME:   |  |  |
| DOSE/STRENGTH: FREQUENCY:  | LENGTH OF QUANTITY:  |  |
|  | THERAPY/REFILLS:   |  |
| NEW THERAPY RENEWAL  | IF RENEWAL: DATE THERAPY INITIATED:  |  |
| DURATION OF THERAPY (SPECIFIC DATES):  |  |  |

Continued on next page.



## Tadliq (tadalafil susp) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

## MEMBER'S LAST NAME: MEMBER'S FIRST NAME:

| 1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? YES (if yes, complete below) NO  |   |                                       |  |
|---|---|---------------------------------------|--|
| MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):  | <b>DURATION OF THERAPY</b> (SPECIFY DATES): | RESPONSE/REASON FOR FAILURE/ALLERGY:  |  |
| 2. LIST DIAGNOSES:  |   | ICD-10:                               |  |
| □ Pulmonary Arterial Hypertension(PAH)  |   |                                       |  |
| □ Other diagnosis:ICD-:   | 10  |                                       |  |
| <b>3. REQUIRED CLINICAL INFORMATION:</b> PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.   |   |                                       |  |
| Clinical Information: Is the drug going to be used in conjunction with a clinical trial? □ Yes □ No   |   |                                       |  |
| Is prescriber a pulmonologist, cardiologist, nephrologist, or rheumatologist? ☐ Yes ☐ No  |   |                                       |  |
| Does patient have WHO Group 1 Pulmonary Arterial Hypertension (PAH), defined as being caused by one of the following etiologies?   Place Provide documentation.  Idiopathic / primary (PAH) |   |                                       |  |
| ☐ Drugs and toxins induced(not reactive treatment)  | ve to acute vasoreactivity testing(AVT) o   | or failed calcium channel blocker)CCB |  |
| ☐ Tissue disease(e.g.,Lupus/SLE, RA scleroderma, systemic sclerosis, CREST syndrome, polymyositis, polyarteritis nodosa, mixed connective tissue disease)                                   |   |                                       |  |
| □ HIV infection   |   |                                       |  |
| □ Portal hypertension   |   |                                       |  |
| □ Congenital heart disease (e.g. atrial-septal defect)  |   |                                       |  |
| ☐ Associated with surgical repair of a congenital systemic-to-pulmonary shunt of at least 1year in duration(e.g., ventricular septal defect, patent ductus arteriosus)                      |   |                                       |  |
| □ Schistosomiasis   |   |                                       |  |
| ☐ Chronic hemolytic anemia  |   |                                       |  |
| Is patient WHO functional class II thru   | IV?   Yes   No please provide docume        | ntation.                              |  |
| Does patient have a mean pulmonary artery pressure(mPAP) equaling 25mmHg or greater? $\Box$ Yes $\Box$ No Please provide cardiac catheterization report.                                    |   |                                       |  |
| Does patient have a pulmonary capillary wedge pressure(PCWP) equaling 15mmHg or less? $\Box$ Yes $\Box$ No Please provide cardiac catheterization report.                                   |   |                                       |  |



## Tadliq (tadalafil susp) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

| MEMBER'S LAST NAME:   | MEMBER'S FIRST NAME:  |  |
|---|---|--|
| Does patient have a pulmonary vascular resistance(PVR)  | equaling 3 Wood units via right heart cath or greater?  |  |
| Yes □ No Please provide cardiac catheterization report.   |   |  |
|   |   |  |
| Does patient have a history of left-sided heart disease?   Yes  No please provide documentation   |   |  |
| Does patient have severe renal insufficiency? ☐ Yes ☐ No please provide documentation   |   |  |
| Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review? |   |  |
|   |   |  |
|   |   |  |
| *Please note: Not all drugs/diagnoses are covered on all plans. This request may be denied unless all required  |   |  |
| information is received.  |   |  |
| <b>ATTESTATION:</b> I attest the information provided is true and accurate to the best of my knowledge. I understand that                                     |   |  |
| the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical  |   |  |
| information necessary to verify the accuracy of the information   | ation reported on this form.  |  |
|   |   |  |
| Prescriber Signature or Electronic I.D. Verification:   | Date:   |  |
|   | ssion contain confidential health information that is legally privileged. If closure, copying, distribution, or action taken in reliance on the contents mation in error, please notify the sender immediately (via return FAX) |  |

**FAX THIS FORM TO: 800-424-7640** 

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

